drugset / Trial / NCT05815394
177Lu-labeled NY108 SPECT Imaging in Patients
NaSingle-groupOpen-labelTreatment
Summary
This is a single arm study to evaluate the safety and biodistribution of 177Lu-labeled NY108 (177Lu-NY108) SPECT Imaging in patients.
Timeline
- Start
- 2023-03-03
- Primary completion
- 2024-03-03
- Completion
- 2024-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | 177Lu-labeled NY108 | Diagnostic / imaging agent | 40 ug | — |
| Subject | 177Lu-labeled NY108 | Diagnostic / imaging agent | 60 ug | — |
| Subject | 177Lu-labeled NY108 | Diagnostic / imaging agent | 1054.5 mbq | — |
| Subject | 177Lu-labeled NY108 | Diagnostic / imaging agent | 1165.5 mbq | — |